Co-Authors
This is a "connection" page, showing publications co-authored by NAOTO T UENO and RENATA FERRAROTTO.
Connection Strength
0.150
-
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 11; 33(11):1204-1206.
Score: 0.053
-
Reply to: 'Real-world prevalence across 159?872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et?al. Ann Oncol. 2021 09; 32(9):1194-1197.
Score: 0.049
-
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021 05; 32(5):661-672.
Score: 0.048